Oppenheimer Maintains Outperform on DexCom, Lowers Price Target to $105
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Steven Lichtman maintains an Outperform rating on DexCom (NASDAQ:DXCM) but lowers the price target from $115 to $105.
October 25, 2024 | 3:55 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Oppenheimer has maintained its Outperform rating for DexCom but has lowered the price target from $115 to $105, indicating a more cautious outlook.
The maintenance of an Outperform rating suggests continued confidence in DexCom's performance, but the lowered price target indicates a more cautious outlook, likely due to market conditions or company-specific factors. This could lead to a short-term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100